Listed

Integer Holdings Corp: Form 10-Q for the period ended Apr 3, 2026

Filed with the SEC on Apr 30, 2026 and accepted by EDGAR at Apr 30, 2026, 16:25 ET.

Share

Management's discussion and analysis

As filed, 44,611 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

This Quarterly Report on Form 10-Q should be read in conjunction with the disclosures included in our Annual Report on Form 10-K for the year ended December 31, 2025. In addition, please read this section in conjunction with our Condensed Consolidated Financial Statements and Notes to Condensed Consolidated Financial Statements contained herein.

Cautionary Note Regarding Forward-Looking Statements

Some statements contained in this report and other written and oral statements made from time to time by us and our representatives are not statements of historical or current fact. As such, they are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Exchange Act, and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations, and these statements are subject to known and unknown risks, uncertainties and assumptions. Forward-looking statements include, but are not limited to, statements relating to:

  • supply chain pressures on the Company and our business;
  • future development and expected growth of our business and industry;
  • the success of our acquisition strategy;
  • our ability to develop new innovative products;
  • our ability to execute our business model and our business strategy;
  • the outcome of a strategic review process;
  • the pipeline of opportunities we intend to pursue in our markets, as well as the timing of launch and value of new products;
  • having available sufficient cash and borrowing capacity to meet working capital, debt service and capital expenditure requirements for the next twelve months; and
  • projected contractual debt service obligations.

You can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “forecast,” “outlook,” “assume,” “potential” or “continue” or variations or the negative counterparts of these terms or other comparable terminology. These statements are only predictions and are no guarantee of future performance, and investors should not place undue reliance on forward-looking statements as predictive of future results. Actual events or results may differ materially from those stated or implied by these forward-looking statements. In evaluating these statements and our prospects, you should carefully consider the factors set forth below. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by these cautionary factors and to others contained throughout this report. We disclaim any obligation to publicly update or revise the forward-looking statements made in this report as a result of new information, future events or otherwise, except as required by law.

- 30 -

While it is not possible to create a comprehensive list of all factors that may cause actual results to differ from results expressed or implied by our forward-looking statements or that may affect our future results, some of these factors include, but in no way are limited to, the following:

  • operational risks, such as our dependence upon a limited number of customers; reductions, delays or cancellations in demand from any significant customer or group of customers; pricing pressures and contractual pricing restraints we face from customers; our reliance on third-party suppliers for raw materials, key products and subcomponents; the cost of raw materials, products and subcomponent that are incorporated into our products; trade regulations; changes in order forecasts; our ability to predict and meet the demand for our products; interruptions in our manufacturing operations; uncertainty surrounding macroeconomic and geopolitical factors in the U.S. and globally; our ability to attract, train and retain a sufficient number of qualified associates to maintain and grow our business; the potential for harm to our reputation and competitive advantage caused by quality problems related to our products; our ability to successfully implement a new global enterprise resource planning (“ERP”) solution; our dependence upon our information technology systems and our ability to prevent cyber-attacks and other failures; global climate change and the emphasis on ESG (as defined below) matters by various stakeholders; our dependence upon our senior management team and key technical personnel; and consolidation in the healthcare industry both at a competitor and customer level, resulting in increased competition and pricing pressure;
  • strategic risks, such as the intense competition we face and our ability to successfully market our current or new products; our ability to recover the R&D investments made in the development of new products; our customers in-sourcing or dual sourcing production; our ability to respond to changes in technology; our ability to develop new products and expand into new geographic and product markets; and our ability to successfully identify, make and integrate acquisitions to expand and develop our business in accordance with expectations;
  • market, financial and indebtedness risks, such as our ability to accurately forecast future performance based on operating results that often fluctuate; the volatility of our stock price; our failure to meet our publicly announced outlook; the ability of our stock purchase program to enhance stockholder value; stockholder activism; our significant amount of outstanding indebtedness and our ability to remain in compliance with financial and other covenants under the credit agreement governing our senior secured credit facilities (“Senior Secured Credit Facilities”); economic and credit market uncertainties that could interrupt our access to capital markets, borrowings or financial transactions; the conditional conversion feature of the 2028 Notes (as defined below) and the 2030 Notes (as defined below) adversely impacting our liquidity; the conversion of our 2028 Notes and 2030 Notes; diluting ownership interests of existing holders of our common stock; the counterparty risk associated with our capped call transaction; the counter financial and market risks related to our international operations and sales; our complex international tax profile; and our ability to realize the full value of our intangible assets;
  • legal and compliance risks, such as legal proceedings against us; regulatory issues resulting from product complaints, recalls or regulatory audits; the potential of becoming subject to product liability or intellectual property claims; our ability to protect our intellectual property and proprietary rights; our ability to comply with customer-driven policies and third-party standards or certification requirements; our ability to obtain and/or retain necessary licenses from third parties for new technologies; our ability and the cost to comply with environmental regulations; legal and regulatory risks from our international operations; the fact that the healthcare industry is highly regulated and subject to various regulatory changes; and our business being indirectly subject to healthcare industry cost containment measures and third-party coverage and reimbursement policies that could result in reduced sales of our products; and
  • other risks and uncertainties that arise from time to time.

Unless otherwise noted, any forward-looking statement made by us in this Form 10-Q is based only on information currently available to us and speaks only as of the date on which it is made. Except as may be required by applicable law, we disclaim any obligation to update forward-looking statements in this Form 10-Q whether to reflect changed assumptions, the occurrence of unanticipated events or changes in future operating results, financial conditions or prospects, or otherwise.

In this Form 10-Q, references to “Integer,” “we,” “us,” “our” and the “Company” mean Integer Holdings Corporation and its subsidiaries, unless the context indicates otherwise.

- 31 -

Our Business

Integer Holdings Corporation is one of the largest medical device contract development and manufacturing organizations in the world, serving the cardio and vascular, neuromodulation, and cardiac rhythm management markets. As a strategic partner of choice, we advance the goals of our medical device customers through industry-leading engineering and manufacturing, with a relentless commitment to quality, service, and innovation.

We operate our business in one segment and derive our revenues from three product lines: Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation and Other Markets.

The first quarters of 2026 and 2025 ended on April 3, 2026 and March 28, 2025, respectively, and consisted of 93 days and 87 days, respectively.

Impact of Global Events

Our future results of operations and liquidity could be materially adversely affected by uncertainty surrounding macroeconomic and geopolitical factors in the U.S. and globally characterized by the supply chain environment, inflationary pressure, changes in interest rates, disruptions in the commodities’ markets or in supply chain as a result of wars in Ukraine and the Middle East, and the tensions in Asia relating to China and Taiwan, and the introduction of or changes in tariffs or trade barriers. The impact of these issues on our business will vary by geographic market and product line, but specific impacts to our business may include increased borrowing costs, labor shortages, disruptions in the supply chain, delayed or reduced customer orders and sales, delays in shipments to and from certain countries and potential increased expenses resulting from tariffs or other trade barriers.

We monitor economic conditions closely. In response to reductions in revenue, we can take actions to align our cost structure with changes in demand and manage our working capital. However, there can be no assurance as to the effectiveness of our efforts to mitigate any impact of the current and future adverse economic conditions and other developments.

Sales Outlook

In 2026, we expect year over year sales growth to be primarily impacted by lower sales related to three new products due to lower than anticipated market adoption. We believe the magnitude of these changes on multiple products at the same time is highly unusual.

Strategic Review

In April 2026, we announced that the Board had initiated a strategic review to maximize stockholder value. We are considering a full range of potential opportunities including, but not limited to, a sale, merger, or strategic business combination as compared to the value creation opportunities from continued execution of the Company’s standalone strategy. There is no deadline or definitive timeline set for the completion of the strategic review, and there can be no assurance that the review will result in any transaction or other outcome.

Business Acquisitions

We selectively evaluate acquisitions as a means to acquire additional technology or manufacturing capabilities to expand our product offering in our key existing growth markets. Consistent with our tuck-in acquisition strategy, since the beginning of 2022 we have completed the following acquisitions, including those that impact the comparability of our results between periods:

On December 4, 2025, we acquired certain assets of Biocoat. Prior to the acquisition, Biocoat was a privately-held manufacturer specializing in high value surface coating technology platforms, including UV and thermal cure hydrophilic coatings.

On February 28, 2025, we acquired substantially all of the assets and assumed certain liabilities of VSi. Prior to the acquisition, VSi was a privately-held full-service provider of parylene coating solutions, primarily focused on complex medical device applications.

On January 7, 2025, we acquired substantially all of the assets and assumed certain liabilities of Precision. Prior to the acquisition, Precision was a privately-held manufacturer specializing in high value surface coating technology platforms, including fluoropolymer, anodic coatings, ion treatment solutions and laser processing.

Refer to Note 2, “Business Acquisitions” of the Notes to Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information about the transactions above.

- 32 -

Financial Overview

Income (loss) from continuing operations for the first quarter of 2026 was income of $16.5 million, or $0.48 per diluted share, compared to a loss of $22.5 million, or $0.66 per diluted share, for the first quarter of 2025. These variances are primarily the result of the following:

  • Sales for the first quarter of 2026 increased $2.2 million when compared to the same period in 2025, driven by higher Cardio & Vascular and Cardiac Rhythm Management & Neuromodulation sales, partially offset by lower Other Markets.
  • Gross profit for the first quarter of 2026 decreased $10.7 million, primarily by driven by lower fixed cost absorption due to lower production volumes.
  • Operating expenses for the first quarter of 2026 increased $7.0 million when compared to the same period in 2025, primarily due to higher SG&A and RD&E costs, partially offset by and Restructuring and other charges. Operating expenses as a percentage of sales improved to 17.7% for the first quarter of 2026 compared to 16.2% or the first quarter of 2025.
  • Interest expense for the first quarter of 2026 decreased $5.1 million compared to the same period in 2025, primarily due to lower interest rates on our outstanding borrowings.
  • During the first quarters of 2026 and 2025, we recognized losses on equity investments of $1.5 million compared to gains of $0.2 million, respectively. Gains and losses on equity investments are generally unpredictable in nature.
  • Other loss, net for the first quarter of 2026 was $0.3 million compared to $47.9 million for the first quarter of 2025. The first quarter of 2025 includes $46.7 million of debt conversion inducement expense related to the partial exchange of our outstanding 2028 Notes that was completed during the first quarter of 2025.
  • We recorded provisions for income taxes for the first quarters of 2026 and 2025 of $3.8 million and $9.5 million, respectively. The change in income tax expense was primarily due to relative changes in pre-tax income and the impact of discrete tax items.

- 33 -

Our Financial Results

The following table presents selected financial information derived from our Condensed Consolidated Financial Statements, contained in Item 1 of this report, for the periods presented (dollars in thousands, except per share).

Product Line Sales: Three Months Ended April 3, 2026 March 28, 2025 Change $%
Cardio & Vascular $261,733 $258,871 $2,862 1.1%
Cardiac Rhythm Management & Neuromodulation 168,264 160,345 7,919 4.9%
Other Markets 9,583 18,176 (8,593) (47.3)%
Total sales 439,580 437,392 2,188 0.5%
Cost of sales 329,985 317,074 12,911 4.1%
Gross profit 109,595 120,318 (10,723) (8.9)%
Gross profit as a % of sales 24.9% 27.5%
Operating expenses:
Selling, general and administrative (“SG&A”) 58,711 51,160 7,551 14.8%
SG&A as a % of sales 13.4% 11.7%
Research, development and engineering (“RD&E”) 16,243 14,201 2,042 14.4%
RD&E as a % of sales 3.7% 3.2%
Restructuring and other charges 2,772 5,405 (2,633) (48.7)%
Total operating expenses 77,726 70,766 6,960 9.8%
Operating income 31,869 49,552 (17,683) (35.7)%
Operating expense as a % of sales 17.7% 16.2%
Operating income as a % of sales (“Operating margin”) 7.2% 11.3%
Interest expense 9,734 14,805 (5,071) (34.3)%
(Gain) loss on equity investments 1,468 (181) 1,649 NM
Other loss, net 316 47,927 (47,611) (99.3)%
Income (loss) from continuing operations before taxes 20,351 (12,999) 33,350 NM
Provision for income taxes 3,845 9,466 (5,621) (59.4)%
Effective tax rate 18.9% (72.8)%
Income (loss) from continuing operations $16,506 $(22,465) $38,971 NM
Income (loss) from continuing operations as a % of sales 3.8% (5.1)%
Diluted earnings (loss) per share from continuing operations $0.48 $(0.66) $1.14 NM

NM - Calculated change not meaningful.

- 34 -

Product Line Sales

Three Months Ended April 3, 2026 March 28, 2025 Change $%
Cardio & Vascular $261,733 $258,871 $2,862 1.1%
Cardiac Rhythm Management & Neuromodulation 168,264 160,345 7,919 4.9
Other Markets 9,583 18,176 (8,593) (47.3)
Total sales $439,580 439580 $437,392 $2,188 0.5

For the first quarter of 2026, Cardio & Vascular (“C&V”) sales increased $2.9 million, or 1%, versus the comparable 2025 period. C&V sales for the first quarter of 2026 included $2.7 million in incremental sales from our 2025 acquisitions. Foreign currency exchange rate fluctuations increased C&V sales for the first quarter of 2026 by $1.2 million in comparison to the 2025 period, primarily due to U.S. dollar fluctuations relative to the Euro.

For the first quarter of 2026, Cardiac Rhythm Management & Neuromodulation (“CRM&N”) sales increased $7.9 million, or 5%, versus the comparable 2025 period, driven by Cardiac Rhythm Management growth, partially offset by lower sales due to a Neuromodulation customer. Foreign currency exchange rate fluctuations did not have a material impact on CRM&N sales during the first quarter of 2026 in comparison to 2025.

Other Markets sales for the first quarter of 2026 decreased $8.6 million, or 47%, versus the comparable 2025 period, driven by execution of the Portable Medical Exit. Foreign currency exchange rate fluctuations did not have a material impact on Other Markets sales during the first quarter of 2026 in comparison to 2025.

Gross Profit

Three Months Ended April 3, 2026 March 28, 2025 Change $%
Gross profit (in thousands) $109,595 $120,318 $(10,723) (8.9)%
Gross margin 24.9% 27.5%

Gross margin declined in the first quarter of 2026, compared to the same prior year period due to the negative impact of lower fixed cost absorption, partly offset by on-going cost reduction initiatives. Gross margin, or gross profit as a percentage of sales, has been and will continue to be affected by a variety of factors, including the average sales price of our products and services and transaction volume growth. We expect our gross margin to fluctuate over time.

- 35 -

SG&A Expenses

Changes to SG&A expenses from the prior year periods were due to the following (in thousands):

Three Months Ended April 3, 2026 March 28, 2025 Change $%
Compensation and benefits(a) $29,032 $27,563 $1,469 5.3%
Depreciation and amortization expense(b) 12,862 11,776 1,086 9.2
Professional fees(c) 7,621 3,340 4,281 128.2
Contract services(d) 5,000 3,979 1,021 25.7
Travel and entertainment 437 1,175 (738) (62.8)
Bank fees and charges 831 832 (1) (0.1)
All other SG&A 2,928 2,495 433 17.4
Total SG&A expense $58,711 $51,160 $7,551 14.8

(a) Compensation and benefits increased primarily due to annual merit increases, acquisitions, leadership transitions, and the execution of our enterprise resource planning system implementation.

(b) Depreciation and amortization expense increased due to amortization of customer list intangible assets related to recent acquisitions.

(c) Professional fees were impacted by advisory fees related to a stockholder activist matter. These activist related costs amounted to $3.2 million for the first quarter of 2026. As a result of the previously disclosed cooperation agreement reached with the activist investor in March 2026, we do not anticipate we will incur any further costs related to this matter.

(d) Contract services expense increased primarily due to higher software costs from information technology enhancements.

RD&E

RD&E expense for the first quarter of 2026 was $16.2 million, compared to $14.2 million for the first quarter 2025. The increase in RD&E expense during 2026 compared to 2025 is primarily due to the timing of program milestone achievements for customer funded programs. RD&E expenses are influenced by the number and timing of in-process projects and labor hours and other costs associated with these projects. Our research and development initiatives continue to emphasize new product development, product improvements, and the development of new technological platform innovations.

- 36 -

Restructuring and Other Charges

We continuously evaluate our business and identify opportunities to realign resources to better serve our customers and markets, improve operational efficiency and capabilities, and lower operating costs. To realize the benefits associated with these opportunities, we undertake restructuring-type activities to transform our business. We incur costs associated with these activities, which primarily include exit and disposal costs and other costs directly related to the restructuring initiative. Restructuring charges include exit and disposal costs from these activities. In addition, from time to time, we incur costs associated with acquiring and integrating businesses, and certain other general expenses, including asset impairments.

Restructuring and other charges comprise the following (in thousands):

Three Months Ended April 3, 2026 March 28, 2025 Change $%
Restructuring charges(a) $607 $664 $(57) (8.6)%
Acquisition and integration costs(b) 1,442 4,742 (3,300) (69.6)
Other general expenses(c) 723 (1) 724 NM
Total restructuring and other charges $2,772 $5,405 $(2,633) (48.7)

(a) Restructuring charges for the first three months of 2026 and 2025 primarily consist of costs associated with our strategic reorganization and alignment and manufacturing alignment to support growth initiatives.

(b) Amount for the first three months of 2026 primarily includes $0.7 million of costs related to our investment in a convertible debt instrument during the quarter and integration expenses related to our recent acquisitions. Amount for the first three months of 2025 primarily include acquisition expenses related to the Precision and VSi acquisitions.

(c) Amounts include gains and losses in connection with the disposal of property, plant and equipment.

Refer to Note 8, “Restructuring and Other Charges” of the Notes to Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information regarding these initiatives.

- 37 -

Interest Expense

Information relating to our interest expense is as follows (dollars in thousands):

Three Months Ended April 3, 2026 Amount Rate March 28, 2025 Amount Rate Change Amount Rate (bp)
Contractual interest expense $7,392 2.39% $12,485 4.06% $(5,093) (167)
Amortization of deferred debt issuance costs and original issue discount 1,625 0.54 1,145 0.42 480 12
Losses from extinguishment of debt — — 737 0.25 (737) (25)
Interest expense on borrowings 9,017 2.93% 14,367 4.73% (5,350) (180)
Other interest expense 717 438 279
Total interest expense $9,734 $14,805 $(5,071)

During 2026, contractual interest expense has decreased due to a lower weighted average interest rate, partially offset by a higher average debt balance outstanding. The favorable weighted average interest rate is due to the replacement of some of our higher variable rate debt with lower fixed rate debt through issuance of the 2030 Notes at the end of the first quarter of 2025. The higher average debt balance outstanding is primarily the result of borrowings to fund the 2025 acquisitions and to repurchase common stock.

Other components of interest expense on borrowings include non-cash amortization and write-off (losses from extinguishment of debt) of deferred debt issuance costs and original issue discount. Amortization of deferred debt issuance costs and original issue discount increased during the first quarter of 2026 compared to the same period in 2025 as a result of higher unamortized balances related to new debt. The losses from extinguishment of debt during the first quarter of 2025 were related to prepayments of portions of the TLA Facility, primarily in connection with issuance of our 2030 Notes.

As of April 3, 2026 and December 31, 2025, approximately 88% and 92%, respectively, of our principal amount of debt are fixed rate borrowings.

See Note 6, “Debt,” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information pertaining to our debt.

(Gain) Loss on Equity Investments

(Gain) loss on equity investments for each period were as follows (in thousands):

Three Months Ended April 3, 2026 March 28, 2025 Change $%
Equity method investment (gain) loss $1,468 $(181) $1,649 NM

Equity method investment (gain) loss for both 2026 and 2025 relates to our share of equity method investee gains including unrealized appreciation/depreciation of the underlying interests of the investee. As of April 3, 2026 and December 31, 2025, the carrying value of our equity investments was $6.4 million and $7.9 million, respectively.

See Note 13, “Financial Instruments and Fair Value Measurements” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for further details regarding these investments.

- 38 -

Other Loss, Net

Three Months Ended April 3, 2026 March 28, 2025 Change $%
Foreign currency transaction (gains) losses, net(a) $376 $1,144 $(768) (67)%
Debt conversion inducement expense(b) — 46,681 (46,681) (100)%
Other gains (losses), net (60) 102 (162) (159)%
$316 $47,927 $(47,611) (99)%

(a) Represents gains/losses from the impact of exchange rates on transactions denominated in foreign currencies. Our foreign currency transaction gains/losses are based primarily on fluctuations of the U.S. dollar relative to the Euro, Mexican peso, Uruguayan peso, Malaysian ringgits, or Dominican peso.

(b) Debt conversion inducement expense was recognized in the first quarter of 2025 related to the partial exchange of our outstanding 2028 Notes.

Provision for Income Taxes

Three Months Ended April 3, 2026 March 28, 2025 Change $%
Income (loss) from continuing operations before taxes $20,351 $(12,999) $33,350 NM
Provision for income taxes 3,845 9,466 (5,621) (59)%
Effective tax rate 18.9% (72.8)%

The decrease in the tax provision was primarily due to an increase in R&D tax credits, an increase in tax benefits associated with realized foreign tax credits, and the impact of the non-recurring 2025 expense associated with the net nondeductible induced conversion expenditures incurred as a result of the induced conversion from the exchange of the 2028 Convertible Notes, partially offset by an increase in global minimum tax (Pillar 2).

Our effective tax rate for 2026 differs from the U.S. federal statutory tax rate of 21% due principally to the estimated impact of Federal Tax Credits (including R&D credits and foreign tax credits), and the application of U.S. and foreign international tax rules related to the taxation of global earnings, including Net CFC tested income (“NCTI”), formerly referred to as global intangible low‑tax income (“GILTI”), the deduction associated with foreign‑derived deduction‑eligible income (“FDDEI”), formerly known as foreign‑derived intangible income (“FDII”), and the impact of the OECD’s Pillar Two global minimum tax framework.

NCTI represents income earned by the Company’s controlled foreign corporations that is subject to current U.S. federal income taxation, after consideration of applicable foreign tax credits. NCTI is treated as a period cost and included in the Company’s income tax provision in the period in which the related foreign earnings arise. The amount of NCTI recognized is influenced by the level and mix of foreign earnings, foreign effective tax rates, and the availability of foreign tax credits.

FDDEI provides a deduction that reduces U.S. taxable income generated from certain qualifying foreign sales and services. The benefit recognized from FDDEI depends on the level of qualifying income, overall U.S. taxable income, and statutory limitations.

In addition, our rate is impacted by earnings realized in foreign jurisdictions with statutory rates that are different than the U.S. federal statutory rate. The primary foreign jurisdictions in which we operate and the statutory tax rate for each respective jurisdiction include Switzerland (22%), Mexico (30%), Uruguay (25%), Ireland (12.5%) and Malaysia (24%). Our manufacturing operations in Costa Rica and the Dominican Republic operate under a free trade zone agreement through April 2031 and March 2034, respectively.

In January 2026, the Organization for Economic Cooperation and Development (“OECD”) released administrative guidance recognizing the U.S. minimum tax regime and introducing a “side-by-side” package intended to exempt U.S. parented groups from Pillar 2 minimum taxes imposed by foreign jurisdictions on U.S. earnings. Although full adoption of the guidance is expected to eliminate this exposure with respect to the U.S. jurisdiction, laws to implement the framework have not been enacted in all relevant countries. Accordingly, our financial results reflect the laws enacted and in effect as of April 3, 2026.

- 39 -

Changes in the geographic mix of earnings, foreign income tax rates, the availability of tax credits and deductions, business acquisitions, settlements with taxing authorities, and the continued implementation and interpretation of international tax rules, including NCTI, FDDEI, and Pillar Two, may contribute to volatility in the Company’s effective tax rate in future periods. In addition, we continue to explore tax planning opportunities that may have a material impact on our effective tax rate.

Refer to Note 9, “Income Taxes,” to the accompanying Consolidated Condensed Financial Statements for discussion regarding the Company’s significant tax matters.

Liquidity and Capital Resources

Sources of Liquidity

(dollars in thousands)

April 3, 2026 December 31, 2025
Cash and cash equivalents $8,115 $17,161
Working capital from continuing operations $568,420 $538,056
Current ratio from continuing operations 3.75 3.32

Cash and cash equivalents at April 3, 2026 decreased by $9.0 million from December 31, 2025. Cash generated by operating activities of $24.7 million and proceeds from net borrowings on our revolving credit facility of $65.0 million were primarily offset by purchases of property, plant and equipment of $24.0 million, $50.0 million of repurchases of common stock, a $14.0 million investment in a convertible debt instrument, and tax withholding payments related to net share settlements of restricted stock unit awards of $9.0 million.

Working capital increased by $30.4 million from December 31, 2025, or $39.4 million excluding the decrease in cash and cash equivalents. The increase in working capital, exclusive of cash and cash equivalents, primarily relates to positive fluctuations in inventory and accrued expenses and other liabilities, which were partially offset by a decrease in accounts receivable from the favorable timing of customer payments.

At April 3, 2026, $5.6 million of our cash and cash equivalents were held by foreign subsidiaries. We intend to limit our distributions from foreign subsidiaries to previously taxed income or current period earnings. If distributions are made utilizing current period earnings, we will record foreign withholding taxes in the period of the distribution.

As of April 3, 2026, our capital structure consisted of $1,251.5 million of debt, net of deferred debt issuance costs and unamortized discounts and 34 million shares of common stock outstanding. As of April 3, 2026, we had access to $729.7 million of borrowing capacity under our Revolving Credit Facility, available for normal course of business and letters of credit, and are authorized to issue up to 100 million shares of common stock and 100 million shares of preferred stock. As of April 3, 2026, our contractual debt service obligations for the remainder of 2026, consisting of interest on our outstanding debt and commitment fees on the unused portion of the Revolving Credit Facility are estimated to be approximately $17 million. Actual principal and interest payments may be higher if, for instance, the applicable interest rates on our Senior Secured Credit Facilities increase, we borrow additional amounts on our Revolving Credit Facility, or we pay principal amounts in excess of the required minimums reflected in the contractual debt service obligations above.

Based on current expectations, we believe that our projected cash flows provided by operations, available cash and cash equivalents and borrowings under our Revolving Credit Facility are sufficient to meet our working capital, debt service and capital expenditure requirements for the next twelve months. If our future financing needs increase, we may need to arrange additional debt or equity financing. We continually evaluate and consider various financing alternatives to enhance or supplement our existing financial resources. However, we cannot be assured that we will be able to enter into any such arrangements on acceptable terms or at all.

Credit Facilities and 2028 Notes

As of April 3, 2026, we had Senior Secured Credit Facilities that consist of an $800 million Revolving Credit Facility, with $65 million outstanding principal balance, and a TLA Facility with an outstanding principal balance of $91 million. The Revolving Credit Facility and TLA Facility mature on February 15, 2028. The Senior Secured Credit Facilities include a mandatory prepayment provision customary for similar credit facilities.

- 40 -

The Revolving Credit Facility and TLA Facility contain covenants requiring that we maintain (i) a Total Net Leverage Ratio not to exceed 5.00:1.00, subject to increase in certain circumstances following certain qualified acquisitions and (ii) an interest coverage ratio of at least 2.50:1.00. As of April 3, 2026, we were in compliance with these financial covenants. As of April 3, 2026, our Total Net Leverage Ratio, calculated in accordance with our Senior Secured Credit Facilities agreement, was approximately 3.0:1.0. For the twelve month period ended April 3, 2026, our interest coverage ratio, calculated in accordance with our Senior Secured Credit Facilities agreement, was approximately 14.4:1.0.

Failure to comply with these financial covenants would result in an event of default as defined under the Revolving Credit Facility and TLA Facility unless waived by the lenders. An event of default may result in the acceleration of our indebtedness. As a result, management believes that compliance with these covenants is material to us.

Convertible Notes

In March 2025, we issued $1.0 billion aggregate principal amount of 2030 Convertible Notes, which mature on March 15, 2030 and bear interest at a fixed rate of 1.875% per annum. The total net proceeds from the issuance of the 2030 Convertible Notes, after deducting initial purchasers' discounts and commissions and debt issuance costs, were approximately $976 million. We used the net proceeds from the issuance of the 2030 Convertible Notes to pay down our Revolving Credit Facility and TLA Facility, exchange a portion of our 2028 Convertible Notes, and to pay the cost of the capped calls related to the issuance of our 2030 Convertible Notes.

In February 2023, we issued $500 million aggregate principal amount of notes. The 2028 Convertible Notes mature on February 15, 2028 and bear interest at a fixed rate of 2.125% per annum. In March 2025, in connection with the issuance of the 2030 Convertible Notes, the Company used part of the net proceeds therefrom to exchange $383.7 million in aggregate principal amount of the 2028 Convertible Notes in privately-negotiated transactions. As of April 3, 2026, the remaining aggregate principal amount of the 2028 Convertible Notes was $116.3 million.

As of December 31, 2025, the conditions allowing holders of the Convertible Notes to convert had not been met. Any determination regarding the convertibility of the Convertible Notes during future periods will be made in accordance with the terms of the indenture governing the Convertible Notes. These obligations are classified as a long-term liability on the Consolidated Balance Sheet at April 3, 2026.

See Note 6, “Debt” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for a further information on the Company’s outstanding debt.

Share Repurchase Program

On November 4, 2025, we announced that our Board of Directors had approved a share repurchase program authorizing us to repurchase up to an aggregate of $200.0 million of our outstanding common stock (the “Share Repurchase Program”). Under the Share Repurchase Program, we may repurchase shares from time to time on the open market, in privately-negotiated purchases or otherwise. The Share Repurchase Program has no expiration date and will continue until otherwise suspended or terminated. We are not obligated to repurchase any dollar amount or to acquire any specific number of shares and repurchases may be executed at the discretion of management on an opportunistic basis, or pursuant to trading plans or other arrangements. During 2025, we repurchased 698,356 shares of our common stock for a total of $50.0 million.

On February 19, 2026, we entered into an accelerated share repurchase agreement to repurchase $50.0 million of common stock under the Share Repurchase Program. Under the terms of the ASR Agreement, we paid Bank of America $50.0 million on February 19, 2026 and on that date received initial delivery of 462,535 shares of common stock. On April 2, 2026, Bank of America delivered 127,070 additional shares which completed the ASR Agreement totaling 589,605 repurchased shares. The Company used available cash and borrowings under our credit facility to fund the repurchase of the common shares under the ASR Agreement. As of April 3, 2026, the Company had $100 million of capacity remaining under the Share Repurchase Program.

Factoring Arrangements

We utilize accounts receivable factoring arrangements with financial institutions to accelerate the timing of cash receipts and enhance our cash position. These arrangements, in all cases, do not contain recourse provisions, which would obligate us in the event of our customers’ failure to pay. During the first three months of 2026 and 2025, we sold, without recourse, $10.1 million and $58.1 million of accounts receivable, respectively. See Note 3, “Supplemental Financial Statement Disclosures” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for further information regarding our factoring arrangements.

- 41 -

Summary of Cash Flow

The following cash flow summary information includes cash flows related to discontinued operations.

(in thousands)

Cash provided by (used in): Three Months Ended April 3, 2026 March 28, 2025
Operating activities $24,695 $31,276
Investing activities (37,901) (197,167)
Financing activities 3,830 151,578
Effect of foreign currency exchange rates on cash and cash equivalents 330 (519)
Net change in cash and cash equivalents $(9,046) $(14,832)

Operating Activities – During the first three months of 2026, we generated cash from operations of $24.7 million, compared to $31.3 million for the first three months of 2025, as a $7.2 million decrease in net income adjusted for non-cash items such as depreciation and amortization was partially offset by a decrease in cash flow provided by changes in operating assets and liabilities.

Investing Activities – The $159.3 million decrease in net cash used in investing activities was primarily attributable to lower cash paid for acquisitions offset by the purchase of a long-term investment. Investing activities for the first three months of 2025 included net cash paid of $171.8 million for the Precision and VSi acquisitions.

Financing Activities – Net cash provided by financing activities for the first three months of 2026 was $3.8 million compared to $151.6 million provided by financing activities for the first three months of 2025. In the first three months of 2026, net proceeds of $65.0 million were received from net borrowings under our revolving credit facility and were primarily offset by cash payments of $50.0 million for repurchases of common stock and $9.0 million related to stock-based compensation activity. In the first three months of 2025, the Company received net proceeds from the issuance of our 2030 Notes of $977.5 million, which was partially offset by a $71.0 million purchase of capped call options associated with the 2030 Notes, $383.7 million in aggregate principal amount of exchanged 2028 Notes, $230.0 million of principal payments on our TLA Facility, $126.0 million net payments on our Revolving Credit Facility, and $14.1 million related to stock-based compensation activity.

Off-Balance Sheet Arrangements

We do not currently have off balance sheet arrangements that have or are reasonably likely to have a material current or future effect on our Condensed Consolidated Financial Statements.

Impact of Recently Issued Accounting Standards

In the normal course of business, we evaluate all new accounting pronouncements issued by the FASB, SEC, or other authoritative accounting bodies to determine the potential impact they may have on our Condensed Consolidated Financial Statements. See Note 1, “Basis of Presentation” of the Notes to Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information about these recently issued accounting standards and their potential impact on our financial condition or results of operations.

Critical Accounting Policies and Estimates

The preparation of our Condensed Consolidated Financial Statements in accordance with accounting principles generally accepted in the U.S. requires management to make estimates, assumptions and judgments that affect the amounts reported in the financial statements and accompanying notes. Our estimates, assumptions and judgments are based on historical experience and various other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying amount of assets and liabilities that are not readily apparent from other sources. Making estimates, assumptions and judgments about future events is inherently unpredictable and is subject to significant uncertainties, some of which are beyond our control. Management believes the estimates, assumptions and judgments employed and resulting balances reported in the Condensed Consolidated Financial Statements are reasonable; however, actual results could differ materially.

There have been no significant changes to the critical accounting policies and estimates as compared to those disclosed in Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2025.

- 42 -

Market risk

As filed, 188 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

There have been no material changes to the Company’s exposure to market risk from the information provided in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025.

Controls and procedures

As filed, 1,412 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

a. Evaluation of Disclosure Controls and Procedures

Our management, including the principal executive officer and principal financial officer, evaluated our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) related to the recording, processing, summarization and reporting of information in our reports that we file with the Securities and Exchange Commission as of April 3, 2026. These disclosure controls and procedures have been designed to provide reasonable assurance that material information relating to us, including our subsidiaries, is made known to our management, including these officers, by our employees, and that this information is recorded, processed, summarized, evaluated and reported, as applicable, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Based on their evaluation, as of April 3, 2026, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures are effective.

b. Changes in Internal Control Over Financial Reporting

During the Company’s most recent fiscal quarter, there have been no changes in the Company’s internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

- 43 -

Risk factors

As filed, 3,062 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Except as set forth below, there have been no material changes to the Company’s risk factors as previously disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025.

We are conducting a strategic review of our business and opportunities, and we may not be successful in identifying, pursuing or completing any strategic transaction, and any such strategic transaction, if completed, may not result in additional value for our stockholders. Additionally, we cannot ensure that the strategic review process will not have an adverse impact on our business.

In April 2026, we announced that the Board had initiated a strategic review to maximize stockholder value. We are considering a full range of potential opportunities including, but not limited to, a sale, merger, or strategic business combination as compared to the value creation opportunities from continued execution of the Company’s standalone strategy. We expect to devote substantial time and resources to exploring strategic alternatives with the goal of maximizing stockholder value. However, this strategic review process may not result in our identifying or pursuing any transaction. In the event that we pursue any transaction, we cannot be sure that such transaction will be completed on attractive terms or at all. If any such transaction is consummated it may not lead to increased stockholder value or result in other anticipated benefits. Further, any such transaction could have a variety of negative consequences, and we may pursue or implement a course of action or consummate a transaction that yields unexpected results that adversely affect our business and stockholder value. We have not set a timetable for completion of this strategic review process, and our Board of Directors has not approved a definitive course of action.

Additionally, the process of evaluating these strategic options may be costly, time-consuming, complex and disruptive to our business operations, and we expect to incur significant resources and costs related to this evaluation, such as management’s attention and resources, legal and accounting fees and expenses and other related charges. We may also incur additional unanticipated expenses in connection with this process. We expect a considerable portion of these costs to be incurred regardless of whether any such course of action is identified, implemented or consummated.

If we are not successful in identifying or pursuing a strategic alternative, or if our plans are not executed or consummated in a timely manner, we may suffer reputational harm, and the value of our shares may be adversely affected. In addition, speculation regarding any developments related to the review or pursuit of strategic alternatives and perceived uncertainties related to the future of our business could cause the market price of our shares to fluctuate significantly. Any of the foregoing could have a material adverse effect on our business, prospects, liquidity, financial condition, and results of operations.

- 44 -

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2026-04-03. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2026-01-01 to 2026-04-03$439.6mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2026-01-01 to 2026-04-03$330.0mus-gaap:CostOfGoodsAndServicesSold
Gross profit3 months2026-01-01 to 2026-04-03$109.6mus-gaap:GrossProfit
Selling, general and administrative3 months2026-01-01 to 2026-04-03$58.7mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2026-01-01 to 2026-04-03$31.9mus-gaap:OperatingIncomeLoss
Interest expense3 months2026-01-01 to 2026-04-03$9.7mus-gaap:InterestExpenseNonoperating
Income tax3 months2026-01-01 to 2026-04-03$3.8mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2026-01-01 to 2026-04-03$16.5mus-gaap:NetIncomeLoss
Diluted EPS3 months2026-01-01 to 2026-04-03$0.48us-gaap:EarningsPerShareDiluted
Basic EPS3 months2026-01-01 to 2026-04-03$0.48us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2026-01-01 to 2026-04-0334,433,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow3 months2026-01-01 to 2026-04-03$24.7mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2026-01-01 to 2026-04-03$24.0mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Share repurchases3 months2026-01-01 to 2026-04-03$50.0mus-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2026-04-03$8.1mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2026-04-03$774.8mus-gaap:AssetsCurrent
Total assetsAt period end2026-04-03$3.41bnus-gaap:Assets
Current liabilitiesAt period end2026-04-03$206.3mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2026-04-03$1.71bnus-gaap:Liabilities
Long-term debtAt period end2026-04-03$1.25bnus-gaap:LongTermDebtNoncurrent
Current portion of debtAt period end2026-04-03$0us-gaap:LongTermDebtCurrent
Shareholders' equityAt period end2026-04-03$1.70bnus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001114483-26-000015. Last ingested by Listed: Nov 11, 2026, 00:08 ET. Listed shows no prices and gives no investment advice.